Clinical Trials Logo

Brain Tumors clinical trials

View clinical trials related to Brain Tumors.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT01445691 Not yet recruiting - Glioblastoma Clinical Trials

More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery

Start date: November 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and utility of 5-aminolevulinic acid (ALA) for identifying your tumor during surgery. 5-ALA is not FDA approved at this time. When the investigators remove the tumor from your brain, it is important that they remove all of the tumor and not remove parts of normal brain. Sometimes this can be difficult because the tumor can look like normal brain. In some brain tumors, 5-ALA can make the tumors glow red under blue light. This may make it easier for your doctor to take out all of the tumor from your brain. The purpose of this study is to: - Make sure that 5-ALA helps the doctor remove more of the tumor. - Make sure 5-ALA does not cause any side effects. If you do not want to participate in this study, your doctor(s) will still do their best to remove all of the tumor in your brain. Whether or not you join this study will not change your treatment for your brain tumor.

NCT ID: NCT00906516 Not yet recruiting - Brain Tumors Clinical Trials

Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme

Start date: May 2009
Phase: Phase 2
Study type: Interventional

Bradmer Pharmaceuticals, Inc. (Bradmer) is requesting approval to study the safety of Neuradiab® when combined with Bevacizumab (Avastin) therapy given at a minimum of 30 days after Neuradiab administration in patients with a first or second recurrence of glioblastoma multiforme (GBM), in an attempt to manage life threatening recurrence of Grade IV malignant glioma.